10. Amgen – Five Top Class Therapeutics – $ 1.9 billion
In its largest drug delivery-related acquisition, Amgen (NSDQ: AMGN) acquired Five Prime Therapeutics (NSDQ: FPRX) to support its strategy of international expansion and pipeline programs to complement Amgen’s many injectable and oral oncology therapeutics accelerate.
The $ 1.9 billion deal between the two California-based companies adds Five Prime’s pipeline to Amgen’s oncology portfolio, including Five Prime’s leading asset, bemarituzumab.
Bemarituzumab is a first-class, phase 3 anti-FGFR2b antibody for advanced cancer of the stomach or esophagogastric junction. Study results for the therapeutic suggest that FGFR2b could be used in the treatment of other epithelial cancers, including lung, breast, ovarian and more.
“Five Prime fits perfectly into Amgen’s leading oncology portfolio and includes bemarituzumab, a phase 3, first-in-class program in gastric cancer, the world’s third leading cause of cancer death,” Amgen Chair and CEO Robert Bradway said. “In collaboration with the dedicated experts at Five Prime, we plan to rapidly move bemarituzumab into a phase 3 study to bring gastric cancer patients one step closer.”
Here are 10 more big mergers and acquisitions that just missed out on the top 10:
Largest medtech M&A deals in 2021, ranked 11-20 >>
Pages: 1 2 3 4 5 6 7 8 9 10 11 12th